<h3>领取 TipRanks 高级版 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Neuphoria Therapeutics (NEUP) 发布了最新消息。</p>
<p>Neuphoria Therapeutics Inc. 宣布，Spyridon “Spyros” Papapetropoulos 医生于 2023 年 1 月 5 日根据雇佣协议被任命为总裁兼首席执行官，将于 2025 年 12 月 31 日辞去全职总裁兼首席执行官职务，但仍将留任公司董事会成员。根据他的雇佣协议，他将获得相当于其年薪、目标奖金和医疗保险费用的遣散费，部分将在 2025 年支付，其余部分将在 2026 年分期支付，他参与的大多数员工福利计划将立即结束，尽管他现有的股票期权将继续归属并可根据公司的股权计划行使。同时，Papapetropoulos 已签署一份咨询协议，自 2026 年 1 月 1 日起生效，期间他将担任临时首席执行官，最长可达十二个月，按小时咨询费支付，限制在每月约 40 小时，以支持计划中的战略交易并监督领导层过渡，如果公司完成战略合并、控制权变更或类似交易，该安排将提前终止。</p>
<p>最近对 (NEUP) 股票的分析师评级为持有，目标价为 4.00 美元。要查看 Neuphoria Therapeutics 股票的完整分析师预测列表，请访问 NEUP 股票预测页面。</p>
<p><strong>Spark 对 NEUP 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，NEUP 的评级为中性。</p>
<p>该评分主要受 FY2025 财务轨迹改善（收入增长、正自由现金流和低杠杆）的推动，部分被持续亏损和波动性抵消。技术面较弱，股票低于主要移动平均线且 MACD 为负，企业事件受到第三阶段试验失败和项目中止的压力；估值因负收益和无股息收益数据而受到限制。</p>
<p>要查看 Spark 对 NEUP 股票的完整报告，请点击这里。</p>
<p><strong>关于 Neuphoria Therapeutics 的更多信息</strong></p>
<p>Neuphoria Therapeutics Inc.，前身为 Bionomics Ltd.，在生物制药领域运营，专注于开发治疗药物及相关临床项目，治理由包括其前首席执行官在内的董事会监督。</p>
<p><strong>平均交易量：</strong> 1,592,902</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 2140 万美元</p>

NEUP

<p>Neuphoria Therapeutics Inc. 宣布首席执行官 Spyridon Papapetropoulos 将于 2025 年 12 月 31 日辞去全职总裁和首席执行官职务，但仍将留任董事会成员。他将于 2026 年 1 月 1 日开始领取遣散费并进入咨询角色，以协助领导层过渡。最新的分析师评级为 NEUP 股票的持有，目标价格为 4.00 美元，反映出由于财务状况改善但仍面临持续亏损和波动，整体前景中性。Neuphoria 专注于生物制药领域的治疗药物开发</p>

<h3>Claim 70% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>领取 TipRanks 高级版 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Neuphoria Therapeutics ( (NEUP) ) has issued an update.</p>
<div class="lb-trans"><p>Neuphoria Therapeutics (NEUP) 发布了最新消息。</p>
</div><p>Neuphoria Therapeutics Inc. announced that Spyridon “Spyros” Papapetropoulos, M.D., who was appointed president and CEO under an employment agreement effective January 5, 2023, will step down as full-time president and CEO effective December 31, 2025, while remaining on the company’s board of directors. Under his employment agreement, he will receive severance equal to his annual base salary, target bonus and medical insurance premiums, paid partly in 2025 and the remainder in installments through 2026, and his participation in most employee benefit programs will end immediately, though his existing stock options will continue to vest and be exercisable under the company’s equity plan. Concurrently, Papapetropoulos has entered into a consulting agreement effective January 1, 2026, under which he will serve as interim CEO for up to twelve months at an hourly consulting rate, limited to roughly 40 hours per month, to support a planned strategic transaction and oversee leadership transition, with the arrangement set to terminate earlier if the company completes a strategic merger, change of control or similar deal.</p>
<div class="lb-trans"><p>Neuphoria Therapeutics Inc. 宣布，Spyridon “Spyros” Papapetropoulos 医生于 2023 年 1 月 5 日根据雇佣协议被任命为总裁兼首席执行官，将于 2025 年 12 月 31 日辞去全职总裁兼首席执行官职务，但仍将留任公司董事会成员。根据他的雇佣协议，他将获得相当于其年薪、目标奖金和医疗保险费用的遣散费，部分将在 2025 年支付，其余部分将在 2026 年分期支付，他参与的大多数员工福利计划将立即结束，尽管他现有的股票期权将继续归属并可根据公司的股权计划行使。同时，Papapetropoulos 已签署一份咨询协议，自 2026 年 1 月 1 日起生效，期间他将担任临时首席执行官，最长可达十二个月，按小时咨询费支付，限制在每月约 40 小时，以支持计划中的战略交易并监督领导层过渡，如果公司完成战略合并、控制权变更或类似交易，该安排将提前终止。</p>
</div><p>The most recent analyst rating on (NEUP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.</p>
<div class="lb-trans"><p>最近对 (NEUP) 股票的分析师评级为持有，目标价为 4.00 美元。要查看 Neuphoria Therapeutics 股票的完整分析师预测列表，请访问 NEUP 股票预测页面。</p>
</div><p><strong>Spark’s Take on NEUP Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 NEUP 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, NEUP is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，NEUP 的评级为中性。</p>
</div><p>The score is driven primarily by improved FY2025 financial trajectory (revenue step-up, positive free cash flow, and low leverage), partially offset by ongoing losses and volatility. Technicals are weak with the stock below major moving averages and negative MACD, and corporate events are pressured by the Phase 3 trial failure and program discontinuation; valuation remains constrained by negative earnings and no dividend yield data.</p>
<div class="lb-trans"><p>该评分主要受 FY2025 财务轨迹改善（收入增长、正自由现金流和低杠杆）的推动，部分被持续亏损和波动性抵消。技术面较弱，股票低于主要移动平均线且 MACD 为负，企业事件受到第三阶段试验失败和项目中止的压力；估值因负收益和无股息收益数据而受到限制。</p>
</div><p>To see Spark’s full report on NEUP stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 NEUP 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Neuphoria Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Neuphoria Therapeutics 的更多信息</strong></p>
</div><p>Neuphoria Therapeutics Inc., formerly Bionomics Ltd., operates in the biopharmaceutical sector, focusing on developing therapeutics and related clinical programs, with governance overseen by a board of directors that includes its former chief executive as a continuing member.</p>
<div class="lb-trans"><p>Neuphoria Therapeutics Inc.，前身为 Bionomics Ltd.，在生物制药领域运营，专注于开发治疗药物及相关临床项目，治理由包括其前首席执行官在内的董事会监督。</p>
</div><p><strong>Average Trading Volume:</strong> 1,592,902</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,592,902</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $21.4M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 2140 万美元</p>
</div>

Neuphoria Therapeutics 宣布首席执行官过渡及咨询角色